4 free views remaining today

obsolete malignant Sertoli-Leydig cell tumor

ICD-10 Codes

Related ICD-10:

Description

Rare Ovarian Tumor: Sertoli-Leydig Cell Tumor

A Sertoli-Leydig cell tumor is a rare and unusual type of ovarian neoplasm, accounting for less than 1% of all ovarian tumors [2]. This malignant sex cord stromal tumor typically occurs in young women and is characterized by manifestations of androgen excess, such as hirsutism, menstrual irregularity, and postmenopausal bleeding [5].

Key Features

  • Rare ovarian tumor, accounting for less than 1% of all ovarian tumors
  • Typically occurs in young women
  • Characterized by manifestations of androgen excess, such as:
    • Hirsutism (excessive hair growth)
    • Menstrual irregularity
    • Postmenopausal bleeding
  • Most are small, unilateral tumors in adults, with the vast majority being benign [3]

Symptoms

The symptoms of Sertoli-Leydig cell tumor can include:

  • Abdominal pain and swelling
  • Amenorrhea (absence of menstruation)
  • Menstrual irregularity
  • Postmenopausal bleeding

These symptoms are a result of the tumor's production of androgens, which can lead to an overproduction of male hormones in women [5].

References

[1] Not applicable (no relevant information found)

[2] Sertoli-Leydig cell tumor, a type of sex cord stromal tumor is an unusual ovarian neoplasm which accounts for less than one percent of ovarian tumors. Majority ... [3]

[3] Second most common type of pure sex cord stromal tumor after Leydig cell tumor; Most are small, unilateral tumors in adults and the vast majority are benign ...

[5] These tumors provoke symptoms and signs including abdominal pain and swelling, amenorrhea, menstrual irregularity, postmenopausal bleeding, ...

Additional Characteristics

  • Rare ovarian tumor
  • Typically occurs in young women
  • Characterized by manifestations of androgen excess
  • Most are small, unilateral tumors in adults, with the vast majority being benign

Signs and Symptoms

Based on the provided context, it appears that there are limited resources available for information on obsolete malignant Sertoli-Leydig cell tumors.

However, I can provide some general information on the symptoms and signs associated with this type of tumor. According to search result [4], virilizing ovarian tumors, including Sertoli-Leydig cell tumors (SLCTs), are rare and account for less than 1% of ovarian tumors.

The symptoms and signs of SLCTs may include:

  • Hormonal manifestations such as hirsutism, male pattern alopecia, and deepening of the voice [6]
  • Abdominal pain and swelling
  • Amenorrhea (absence of menstruation)
  • Menstrual irregularity
  • Postmenopausal bleeding

It's worth noting that these symptoms may not be specific to SLCTs and can be associated with other conditions as well.

In terms of obsolete malignant Sertoli-Leydig cell tumors, I couldn't find any specific information on the signs and symptoms. However, it's possible that the symptoms mentioned above may still be relevant in some cases.

References:

[4] - Introduction: The virilizing ovarian tumors represent less than 1% of ovarian tumors, with the most common being Sertoli-Leydig cell tumor (SLCT). [6] - We report the rare case of a bilateral, metachronous ovarian SLCT in an 11-year-old patient, who developed the tumour on her right ovary.

Additional Symptoms

  • Abdominal pain and swelling
  • Hormonal manifestations such as hirsutism, male pattern alopecia, and deepening of the voice
  • Amenorrhea (absence of menstruation)
  • Menstrual irregularity
  • bleeding

Diagnostic Tests

Based on the provided context, it appears that diagnostic tests for malignant Sertoli-Leydig cell tumors are crucial in determining the appropriate treatment plan.

Imaging Studies

Several imaging studies can aid in diagnosing and characterizing Sertoli-Leydig cell tumors. These include:

  • Scrotal ultrasonography: This study can confirm the diagnosis, especially when physical examination findings are equivocal [5].
  • Magnetic resonance imaging (MRI): MRI can provide additional information and help narrow down the diagnosis range [9].

Tumor Markers

Elevated levels of certain tumor markers can indicate the presence of a Sertoli-Leydig cell tumor. For instance:

  • Alpha-fetoprotein (AFP) tumor marker: An isolated elevation of AFP was observed in one case study, which helped confirm the diagnosis [4].

Histopathological Examination

A definitive diagnosis is often made through histopathological examination of tissue samples. This involves examining the tumor's microscopic features, such as:

  • Microscopic appearance: Sertoli-Leydig cell tumors are composed of large, closely packed cells with eosinophilic cytoplasm [3].
  • Immunohistochemistry: This technique can help distinguish between Sertoli and Leydig cell tumors by identifying specific markers, such as inhibin for Sertoli-Leydig cell tumors [7][8].

Other Diagnostic Tools

While not directly related to the diagnosis of Sertoli-Leydig cell tumors, other diagnostic tools may be useful in evaluating patients with suspected testicular cancer. These include:

  • Computed Tomography (CT) scans: CT scans can provide information on the tumor's size and location [9].
  • Mammograms: Mammograms are not directly related to Sertoli-Leydig cell tumors but may be relevant in cases where concomitant uterine cancers are suspected [11].

It is essential to note that a definitive diagnosis of malignant Sertoli-Leydig cell tumor requires histopathological examination and immunohistochemical analysis. Imaging studies and tumor markers can aid in the diagnostic process, but they should not be relied upon as sole diagnostic tools.

References:

[3] Context 3 [4] Context 4 [5] Context 5 [7] Context 7 [8] Context 8 [9] Context 9

Additional Diagnostic Tests

  • Immunohistochemistry
  • Magnetic resonance imaging (MRI)
  • Scrotal ultrasonography
  • Alpha-fetoprotein (AFP) tumor marker
  • Histopathological Examination
  • Computed Tomography (CT) scans
  • Mammograms

Treatment

Based on the available information, it appears that the treatment for malignant Sertoli-Leydig cell tumors (SLCTs) has evolved over time.

  • In the past, chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VAC) was used as a treatment option [6].
  • However, more recent studies have suggested that other chemotherapeutic agents such as platinums/taxane may be effective in treating SLCTs [5].
  • A case report has also described the successful use of paclitaxel and carboplatin chemotherapy in a patient with recurrent ovarian Sertoli-Leydig cell tumor [3].

It's worth noting that surgery is still considered the primary treatment for SLCTs, with or without chemotherapy based on age, stage of the tumor, and degree of differentiation [8]. However, the optimal treatment algorithm for SLCTs remains unknown due to their rarity.

In terms of specific drug treatments, cisplatin-based chemotherapy has been used as adjuvant therapy for patients with SLCT stage I, poorly differentiated tumors [1]. Additionally, bleomycin-etoposide-platinum chemotherapy has been explored as a treatment option for Leydig cell tumor, which is a related but distinct condition [2].

Overall, while there are some data on the use of specific chemotherapeutic agents in treating malignant SLCTs, more research is needed to determine the most effective treatment approaches.

References:

[1] HP Lashkari · 2013 · Cited by 10 [2] Sep 18, 2023 [3] by S Lim · 2013 · Cited by 6 [5] by J Xiu · 2016 [6] by CA Liggins · 2016 · Cited by 14 [8] by V Gowri · 2012 · Cited by 4

Recommended Medications

  • Vincristine, doxorubicin, and cyclophosphamide (VAC)
  • taxane
  • Paclitaxel and carboplatin chemotherapy
  • Cisplatin-based chemotherapy
  • Bleomycin-etoposide-platinum chemotherapy

💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.

Differential Diagnosis

Based on the provided context, it appears that differential diagnosis for obsolete malignant Sertoli-Leydig cell tumors involves considering various conditions that may present similarly.

  • A rare form of sex cord stromal tumors, Sertoli-Leydig cell tumors (SLCT), have been identified in a portion of

Additional Differential Diagnoses

Additional Information

rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_656
oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:0050618
core#notation
DOID:0050618
rdf-schema#label
obsolete malignant Sertoli-Leydig cell tumor
owl#deprecated
true
relatedICD
http://example.org/icd10/C56.2
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.